Videos

A panel of experts explain what they do within their clinical practices to select second- or later-line therapies for patients with advanced renal cell carcinoma.

Neeraj Agarwal, MD, and Simon Chowdhury, MD, examine the efficacy and safety data presented in the recent publication, “Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.”

Susan M. O’Brien, MD, on common toxicities and adverse effects when treating patients with chronic lymphocytic leukemia.

Dr. Atish Choudhury provides an overview of advances and changes in management of patients with metastatic castration sensitive prostate cancer (mCSPC) in the last decade.

Drs Steven Finkelstein and Louis J. Mazzarelli comment on limitations associated with conventional imaging modalities in prostate cancer and highlight the roles of newer tests such as 18F-fluciclovine and 68Ga-PSMA-11.

Daniel Petrylak, MD and Donald Barry Boyd, MD, MS, examine real-world data presented in the recent publication, “Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.”

Nina Shah, MD, discusses how to properly navigate treatment plans for patients with relapsed/refractory multiple myeloma.

Jennifer A. Woyach, MD, spoke about why it’s important to use newer therapies instead of chemoimmunotherapy for patients with chronic lymphocytic leukemia.

Two oncologists highlight practical considerations when choosing maintenance therapy.

At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about what changes in the treatment of myelofibrosis stood out to him most.

Patient Case 2 is presented, and Dr Gadi and Dr Mahtani detail how they would proceed with treating this patient.

Patient Case 1 is presented to the panel, and Vijayakrishna Gadi, MD, PhD, shares his thoughts on how to approach treatment of this patient.

Experts highlight the benefits of frontline avelumab maintenance therapy in patients with metastatic urothelial carcinoma.

Experts discuss frontline immunotherapy for metastatic urothelial carcinoma when chemotherapy may not be an option.

Susan M. O’Brien, MD, on combination therapies for treating patients with chronic lymphocytic leukemia.

CancerNetwork® spoke with Rafael Fonseca, MD, about the rationale for a simulation using real-world data sets to compare the utility of daratumumab-containing regimens as either frontline or second-line therapy.

Luciano Costa, MD, PhD, spoke about how the results in the final primary analysis of the MASTER trial with daratumumab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma were not what he expected.

Nina Shah, MD, discusses the current treatment options for treating patients with transplant-ineligible multiple myeloma.

Susan M. O’Brien, MD, on treating patients with 17p deletions and TP53 mutations who have chronic lymphocytic leukemia.

Nina Shah, MD, on the current treatment options for treating patients with transplant-eligible multiple myeloma.

At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about big breakthroughs in the treatment of myelofibrosis over the preceding year.

Steven Devine, MD, spoke about which abstracts he found most interesting at ASH 2021.

Dr Braun closes out the clinical trial dialogue by discussing the CONTACT-03 and Tivo-3 trials.

Patient Case 2 continues, and Drs Zhang and Orenstein discuss second-line trials for advanced renal cell carcinoma.

Susan M. O’Brien, MD, on the approved BTK inhibitors for treating chronic lymphocytic leukemia.

Sattva S. Neelapu, MD, spoke about continuing to look at results from the ZUMA-5 trial to determine if axicabtagene ciloleucel can cure patients with relapsed or refractory indolent non-Hodgkin lymphoma

Responses to questions by community hematologists/oncologists regarding optimal ways to diagnose and manage patients with myelofibrosis.

Clinical pearls for planning and sequencing therapy for patients with myelofibrosis.

Nina Shah, MD, discusses the biggest news from the FDA for multiple myeloma in the past year.

When asked about abstracts he thinks have the greatest potential to impact the standard of care in myeloma, Rafael Fonseca, MD, looked to emerging cellular therapies, specifically ciltacabtagene autoleucel for the treatment of heavily pretreated disease.